item management s discussion and analysis of financial condition and results of operations overview since inception  the company has focused on the research and clinical development of products to treat allergies and autoimmune diseases 
the company s primary sources of working capital have been from the sale of equity securities  interest earned on invested capital and sponsored research funding from collaboration agreements 
in  the company expended significant resources on the clinical development of the allervax r cat the company s therapeutic product for individuals allergic to cats and allervax r ragweed the company s therapeutic product for individuals allergic to ragweed pollen products 
a majority of the clinical spending related to a patient clinical trial conducted in the united states for the company s allervax r ragweed product 
the company also incurred costs for two trials for the company s allervax r cat product 
following analysis of the trial data from both the allervax r cat and allervax r ragweed therapeutic trials conducted during and as a result of conversations with the united states food and drug administration fda regarding these programs  the company plans to expend funds for additional trials for both the allervax r cat and allervax r ragweed products in as a result of recently announced changes in management and the composition of the company s board of directors  the company redefined its priorities for product development in march and plans to focus most of its resources in on the efficient development of its allervax r cat and allervax r ragweed therapeutics 
the company s development during also focused on advancing a multiple sclerosis peptide therapeutic to the clinical development stage 
an investigational new drug ind application for an injectable form of this therapeutic was filed with the food and drug administration on december  as a result of the change in focus in the development priorities noted above  the company is reviewing its plans for the development of the multiple sclerosis product 
the company also expects to expend certain funds in for the development of a nonparenteral dosage form of its multiple sclerosis therapeutic 
partial funding for the nonparenteral dosage product is currently being provided by schering ag  germany schering ag 
years ended december  and total revenues in were  compared to  in the increase in total revenues in was primarily due to a  payment received from hoechst marion roussel  inc hmr resolving all obligations related to the collaboration agreement between the company and hmr  which was terminated by hmr on september  revenues in included a license and milestone payment from hmr in the amount of  offsetting this increase  in part  was lower sponsored research funding received under a license and collaboration agreement with schering ag 
sponsored research funding from schering ag was  and  in and  respectively 
total operating expenses were  in compared to  in expenses included  for exit costs relating to the closing of the company s palo alto facility 
research and development expenses were  in compared to  in  an increase of  or 
the increase in research and development expenses was primarily due to increased headcount and related costs in the development  clinical  and regulatory areas to support the continuing clinical development of the allervax r cat and allervax r ragweed products 
in addition  research and development costs increased due to severance payments made and other costs incurred in connection with the resignation of two executive officers of the company during clinical trial costs increased over the prior year  primarily as a result of the seasonal allervax r ragweed trial 
partially offsetting these increases in research and development were savings from reduced headcount and related costs as a result of the closing of the company s palo alto research facility in may general and administrative expenses were  in compared to  in  an increase of  or 
the increase in general and administrative costs was due primarily to severance payments made and other costs incurred in connection with the resignation of three additional executive officers of the company during this was offset in part by lower headcount and related costs as a result of closing the company s palo alto research facility in may net interest income was  in compared to  in  an increase of  or 
the increase resulted primarily from a higher average investable cash and investment balance which was due to the sale of equity securities through two public offerings during the third quarter of this was offset in part by cash spent on operations during in addition  increased interest received from hmr related to capital expenditures made by the company with respect to the joint manufacture of the allervax r family of allergy therapeutics contributed to the increase in interest income 
the net loss decreased in the fourth quarter of as compared to the first three quarters as the result of a one time  payment from hmr 
this payment resolved all outstanding obligations related to the terminated collaboration between the company and hmr for the development of the allervax r products 
years ended december  and total revenues in were  compared to  in the increase in total revenues in was primarily due to  of sponsored research funding under a license and collaboration agreement with schering ag  offset in part by lower milestone payments from hmr 
revenues also included license and milestone payments from hmr of  and  in and  respectively 
total operating expenses were  in compared to  in expenses included  for exit costs related to the closing of the company s palo alto facility 
research and development expenses were  in compared to  in  a decrease of  or 
the decrease in research and development expenses was primarily due to reduced headcount and related costs resulting from the consolidation of the company s research operations and lower start up costs associated with the establishment of an in house gmp grade manufacturing facility  offset in part by increased costs associated with the continuing clinical development of the allervax r cat and allervax r ragweed products 
general and administrative expenses were  in compared to  in  a decrease of  or 
the decrease in general and administrative expenses related primarily to lower salary and related costs as compared to which included severance and other expenses associated with the resignation of an executive officer and other general and administrative staff reductions 
in addition  lower headcount costs as a result of closing the company s palo alto facility contributed to the decrease in general and administrative costs 
net interest income was  in compared to  in  an increase of  or 
the increase resulted primarily from the effect of higher interest rates earned on the company s investments 
in addition  interest received from hmr relating to capital expenditures made by the company with respect to the joint manufacture of the allervax r family of allergy therapeutics contributed to the increase in interest income 
liquidity and capital resources since inception  immulogic has financed its operations through the sale of equity securities  sponsored research revenues  license and milestone payments  and interest earned on invested capital 
the company s total cash and investments balance at december  was  which included cash and cash equivalents of  short term investments of  and long term investments of  the company has raised  from public equity offerings  received  from hmr in payments related to the joint collaboration agreement for its allervax r products   from hmr for a final settlement payment upon the termination of the collaboration agreement between the company and hmr  and  from hmr related to a common stock and a stock option purchase 
in addition  the company has received research support payments of  from schering ag under a joint collaboration agreement for its multiple sclerosis peptide therapeutic product and  in equity financing from schering berlin venture corporation 
the company also received a sbir grant during from nida totaling approximately  to complete the preclinical development of the company s therapy to treat cocaine addiction 
net cash used in operating activities was  in compared to  and  in and  respectively 
as of december   the company had invested  in property and equipment primarily in facility renovations  laboratory equipment  and the buildout of a gmp grade manufacturing facility at the company s waltham  massachusetts headquarters 
in march  to help the company support its capital requirements  the company signed a collaboration agreement with schering ag for the joint development and commercialization of the company s peptide therapeutic to treat multiple sclerosis 
under this agreement  the company would have received up to  in research support  of which has been received through december  and up to  in milestone payments 
the company would pay one third of the costs associated with clinical development and would receive a royalty on net sales  if any 
during  the parties agreed in concept to changes in the collaboration agreement under which milestone payments will be restructured to payments made after successful product demonstration and annual research support funding from schering ag during will be reduced from  to  this funding will be dedicated exclusively to the development of a nonparenterally administered therapeutic product for multiple sclerosis 
the company will fund all clinical development costs for the injectable therapeutic product for multiple sclerosis 
schering ag has the right  at its election  to participate in the development and commercialization of the injectable dosage form 
if schering ag elects to participate  it will be required to reimburse the company for a significant portion of these development costs and will be obligated to make certain milestone payments to the company upon achievement of development milestones 
schering ag has the right to terminate the collaboration agreement upon days prior written notice to the company 
there can be no assurance that schering ag will not terminate the collaboration agreement or that it will devote the resources necessary to develop and commercialize any products resulting from the collaboration 
in february  the company entered into a collaboration agreement with hmr formerly marion merrell dow  inc for the worldwide development and commercialization of injectable dosage forms of five allervax r therapeutics 
at the time of execution of the agreement  hmr made a  payment to the company and through december  had made license and milestone payments of  on march   the company received notification from hmr of its withdrawal from this joint collaboration  effective september  the company and hmr worked together to effect an orderly transition of responsibilities as the allervax r program shifted entirely to the company 
on october   the company received a payment in the amount of  resolving all obligations relating to the program in a manner agreeable to both the company and hmr 
under the terms of the agreement  upon termination of the collaboration the company regained all rights to the allervax r allergy program including all injectable and oral therapeutics and complementary recombinant allergy diagnostics 
the company has expended substantial funds for the research and development of its products  and will continue to expend substantial funds for further research and development  establishment of commercial scale manufacturing capabilities  and the marketing of its products 
the company will seek to obtain additional funds for these purposes through equity or debt financings  collaborative arrangements with corporate partners  or from other sources 
no assurance can be given that such additional funds will be available to the company for such purposes on acceptable terms  if at all 
insufficient funds could require the company to delay  scale back  or eliminate certain of its research and development programs or to license third parties to commercialize products or technologies that the company would otherwise develop or commercialize itself 
the company anticipates that its existing capital resources will enable it to maintain its current and planned operations through at least december  future operating results this annual report to stockholders contains forward looking statements 
for this purpose  any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements 
without limiting the foregoing  the words believes  anticipates  plans  expects  intends and similar expressions are intended to identify forward looking statements 
there are a number of important factors that could cause the company s actual results to differ materially from those indicated by such forward looking statements 
these factors include  without limitation  those set forth below  in the section titled business factors which may affect future results and elsewhere in the company s annual report on form k for the year ended december  the company expects to incur losses for at least the next several years 
the company will require substantial additional funds for its research and product development programs  operating expenses  the pursuit of regulatory approvals and expansion of its production  sales and marketing capabilities 
adequate funds for these purposes  whether through equity or debt financings  collaborative or other arrangements with corporate partners or from other sources  may not be available when needed or on terms acceptable to the company 
insufficient funds could require the company to delay  scale back or eliminate certain of its research product development programs or to license to third parties to commercialize products or technologies that the company would otherwise develop or commercialize itself 
none of the company s products have completed human clinical testing 
although the company s two lead products  allervax r cat and allervax r ragweed  are in clinical development  significant additional development costs will be incurred prior to commercialization 
during  the company expects to incur significant costs in connection with the planned initiation of clinical trials for its allervax r cat and allervax r ragweed product candidates 
there is no assurance that the company s clinical trials will yield favorable results  that the company s products will be granted the required regulatory approvals within the time periods contemplated by the company  or at all  that the company will be able to produce its products in commercial quantities  or that such products will be successfully marketed 
in addition  the company faces intense competition from commercial and academic organizations  many of which are larger and better financed 
the company s strategy for development and commercialization of products depends upon the formation and maintenance of various strategic alliances and licensing arrangements 
in particular  the company has entered into a collaboration with schering ag relating to the development of a therapeutic to treat multiple sclerosis 
schering ag has the right to terminate the collaboration on days notice to the company 
there can be no assurance that the collaboration with schering ag will not be terminated by schering ag or ultimately will be successful 
in addition there can be no assurance that future arrangements can be made when needed or on terms acceptable to the company 
proprietary rights relating to the products  methods and services of the company will be protected from unauthorized use by third parties only to the extent that they are covered by valid and enforceable patents or are maintained in confidence as trade secrets 
there can be no assurance that any pending patent applications relating to the products of the company will result in patents being issued or that any such patents will afford protection against competitors with similar technology 
in addition  the company is aware of one issued european patent and one pending european patent application belonging to third parties which may adversely affect the company s ability to commercialize its multiple sclerosis therapeutic candidate 
if the claims contained in these patents are sustained  the company may need to acquire licenses to those technologies in order to commercialize its multiple sclerosis therapeutic candidate in europe 
the cost or availability of licenses for these technologies is unknown 
there may be additional domestic and foreign patent applications pending of which the company is unaware at this time and which may affect the company s ability to commercialize any of its products if corresponding patents are issued 
it is likely that significant funds would be required to defend any claim that the company infringes a third party patent 
there can be no assurance that any license required under any such patent would be made available 
as recently announced  the company s chief executive officer resigned in december in addition  in march   the majority of the company s board of directors  including the chairman of the board  resigned after consultation with several major stockholders of the company  and five new directors were added to the board to fill those vacancies 
the significant changes in management at the executive and board levels could result in additional shifts in the strategic direction of the company  including changes in priorities of the company s existing development programs 
other factors that may affect the company s future operating results include the inherent risk of product liability claims which may result from the testing  marketing and sale of pharmaceutical products  the company s fluctuations in quarterly operating results  the company s ability to continue to attract and retain qualified management and scientific staff  and its ability to obtain on a timely basis regulatory approvals for the marketing and sale of its products and to compete successfully in the market 
new accounting pronouncement in  the financial accounting standards board released the statement of financial accounting standards no 
sfas  earnings per share 
sfas specifies the computation  presentation  and disclosure requirements for earnings per share and is substantially similar to the standards recently issued by the international accounting standards  earnings per share ias 
sfas is effective for financial statements issued for periods ending after december   including interim periods 
sfas requires restatement of all prior period eps data presented 
management has not yet determined the impact of sfas on the company s financial statements 

